Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections:

Monica L. Bianchini,Meghan N. Jeffres,Jonathan D. Campbell

Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections:

2020

Monica L. Bianchini
Meghan N. Jeffres
Jonathan D. Campbell

Introduction: Carbapenem-resistant organisms (CROs) present a serious public health problem. Limited treatment options has led to increased use of colistin and polymyxin. Since 2014, the US Food an...

Keywords:

Antibiotics
cost effectiveness
Beta-lactamase
Microbiology
Cost-effectiveness analysis
Colistin
Medicine
Pharmacoeconomics
Polymyxin
carbapenem resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations